City Therapeutics, Inc. Common Stock (CTY)

• Market cap: $1.13B
• 1 day: 0%
• 5 days: -2.61%
• 1 month: 0%
• 3 months: 0%
• 6 months: 0%
• Year to date: 0%
• 1 year: 0%
• 5 years: 0%
• 10 years: 0%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.